ANTX (AN2 Therapeutics) Forward Dividend Yield % : 0.00% (As of Mar. 18, 2025)

View and export this data going back to 2022. Start your Free Trial

What is AN2 Therapeutics Forward Dividend Yield %?

As of today (2025-03-18), the Forward Annual Dividend Yield of AN2 Therapeutics is 0.00%.

As of today (2025-03-18), the Trailing Annual Dividend Yield of AN2 Therapeutics is 0.00%.

ANTX's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.43
* Ranked among companies with meaningful Forward Dividend Yield % only.

AN2 Therapeutics's Dividends per Share for the three months ended in Sep. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of AN2 Therapeutics's Forward Dividend Yield %

For the Biotechnology subindustry, AN2 Therapeutics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AN2 Therapeutics's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AN2 Therapeutics's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where AN2 Therapeutics's Forward Dividend Yield % falls into.

AN2 Therapeutics Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

AN2 Therapeutics (NAS:ANTX) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

AN2 Therapeutics Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of AN2 Therapeutics's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

AN2 Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AN2 Therapeutics Inc (NAS:ANTX) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1800 El Camino Real, Suite D, Menlo Park, CA, USA, 94027

Website

https://www.an2therapeutics.com

AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.

Executives

Joshua M Eizen	officer: See Remarks	3023 MONTBRETIA WAY, SAN RAMON CA 94582
Lucy Day	officer: Chief Financial Officer	2032 MIDDLEFIELD ROAD, PALO ALTO CA 94301
Sanjay Chanda	officer: Chief Development Officer	C/O ANACOR PHARMACEUTICALS, INC., 1020 EAST MEADOW CIRCLE, PALO ALTO CA 94303
Robin Shane Readnour	director	3835 CLEGHORN AVENUE, SUITE 300, NASHVILLE TN 37215
Joseph S Zakrzewski	director	509 WATERVIEW PLACE, NEW HOPE PA 18938
Eric Easom	director, officer: Chief Executive Officer	171 FOREST LN., MENLO PARK CA 94025
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Adjuvant Global Health Technology Fund De, L.p.	10 percent owner	C/O ADJUVANT CAPITAL, L.P., 501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017
Kabeer Aziz	director	376 MANHATTAN AVENUE APT. 3, BROOKLYN NY 11211
Kevin Michael Krause	officer: Chief Strategy Officer	369 27TH STREET, SAN FRANCISCO CA 94131
Margaret M Fitzpatrick	director	C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94080
Melvin K Spigelman	director	THE MEDICINES COMPANY, 8 CAMPUS DRIVE, PARSIPPANY NJ 07054
Ra Capital Nexus Fund Ii, L.p.	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Adjuvant Global Health Technology Fund, L.p.	10 percent owner	C/O ADJUVANT CAPITAL, L.P., 501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017
Michael Adrian Nazak	officer: Chief Accounting Officer	5941 OPTICAL COURT, SAN JOSE CA 95138